Tempus AI (NASDAQ:TEM) Shares Up 1.2% – Still a Buy?

Shares of Tempus AI, Inc. (NASDAQ:TEM) traded up 1.2% during mid-day trading on Tuesday . The stock traded as high as $48.64 and last traded at $48.83. 2,780,795 shares were traded during mid-day trading, a decline of 47% from the average session volume of 5,242,936 shares. The stock had previously closed at $48.24.

Analyst Ratings Changes

A number of analysts have weighed in on TEM shares. Bank of America increased their price target on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Loop Capital decreased their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Piper Sandler dropped their price target on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Guggenheim reissued a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Finally, Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.18.

Tempus AI Trading Down 5.5 %

The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a 50 day moving average of $58.62 and a 200 day moving average of $51.55.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.75, for a total value of $190,363,747.50. Following the completion of the sale, the chief executive officer now owns 4,895,589 shares of the company’s stock, valued at approximately $287,615,853.75. The trade was a 39.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,601,969 shares of company stock valued at $317,330,782.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in shares of Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock worth $80,000 after purchasing an additional 278 shares during the last quarter. Geode Capital Management LLC boosted its position in Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the period. Operose Advisors LLC bought a new stake in Tempus AI in the 4th quarter worth $25,000. Prestige Wealth Management Group LLC raised its stake in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. Finally, Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth about $34,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.